465 results on '"Idilman R"'
Search Results
102. 520 RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT-NAIVE VS ADEFOVIR-RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH CHRONIC HEPATITIS B
103. 43 INTERLEUKIN-28B GENE POLYMORHISM MAY AFFECT THE NATURAL COURSE OF HEPATITIS B AND DELTA VIRUS INFECTIONS
104. 525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS
105. OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE
106. T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice
107. Hepatitis B surface antigen seroconversion is associated with favourable long‐term clinical outcomes during lamivudine treatment in HBeAg‐negative chronic hepatitis B patients
108. 723 INTERFERON TREATMENT OF DELTA HEPATITIS: THE LONGER THE DURATION THE BETTER THE SUCCESS?
109. 398 CHARACTERIZATION OF THE INACTIVE HBSAG CARRIER STATE WITH 3 YEAR FOLLOW-UP
110. 731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B
111. P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B
112. F-36 Effectiveness and safety of tenofovir disoproxil fumarate in field practice: A multicenter European cohort study of 737 patients with chronic hepatitis B
113. P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC)
114. Natural history and treatment of chronic delta hepatitis
115. 318 OUTCOME AND VIROLOGICAL CHANGES DURING THE FOLLOW UP OF A LARGE SINGLE CENTER COHORT OF CHRONIC DELTA HEPATITIS PATIENTS
116. Allogeneic Hematopoetic Cell Transplantation In Patients Positive For Hepatitis B Surface Antigen
117. 286 POTENTIAL PROTEOMIC BIOMARKERS IN ASSESSING LIVER FIBROSIS USING SELDI-TOF MS
118. 1027 THE EFFECT OF DIETARY INTERVENTION ON THE LONG-TERM CLINICAL OUTCOME OF NON-ALCOHOLIC FATTY LIVER DISEASE
119. 685 ADEFOVIR TREATMENT OF ENTECAVIR RESISTANCE IN PATIENTS WITH LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B
120. [737] THE EFFECT OF INSULIN-SENSITIZING AGENTS IN THE TREATMENT OF INDIVIDUALS WITH NON-ALCOHOLIC STEATOHEPATITIS
121. [498] HIGH BASELINE HBV-DNA IS LINKED TO THE EMERGENCE OF ADEFOVIR RESISTANCE IN LAMIVUDINE RESISTANT PATIENTS
122. Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation
123. Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables
124. 343 Recipient-derived hepatocytes in sex-mismatched liver allograft after liver transplantation
125. Lamivudine prophylaxis for prevention of chemotherapy induced hepatitis B virus reactivation in hepatitis B virus carriers with hematological malignancies
126. The effect of hepatitis B virus status of the donor on the hepatitis B virus serology of the recipient after allogeneic hematopoietic cell transplantation
127. Increased effective immunogenicity to high‐dose and short‐interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis
128. HFE mutations in chronic hepatitis C
129. Estrogen status contributes to the gender difference in the responseto IFN for chronic hepatitis C
130. Successful Medical Treatment of an Epithelioid Hemangioendothelioma of Liver
131. Hepatic complications of allogeneic hematopoietic cell transplantation.
132. Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters.
133. Indications and criteria for liver transplantation for fulminant hepatic failure.
134. Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant.
135. Hematopoietic stem cell transplantation from nonreplicative hepatitis B virus carriers is safe
136. Cirrhosis in Turner's syndrome: case report and literature review.
137. PPAR-alpha L162V polymorphism in human hepatocellular carcinoma
138. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir
139. The effect of mycophenolate mofetil in steroid refractory or dependent chronic graft-versus-host disease
140. Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)
141. Allogeneic haematopoetic cell transplantation in hepatitis B surface antigen positive recipients
142. EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B
143. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/ oncological malignancies who receive chemotherapy.
144. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
145. The response to interferon + ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race
146. Racial differences in the response to antiviral therapy for chronic hepatitis C
147. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study
148. Advancing the global public health agenda for NAFLD: a consensus statement
149. Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables.
150. Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.